Innocan Pharma's Exciting New Venture in the U.S.
Innocan Pharma Corporation is thrilled to announce a major development as it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) concerning a proposed public offering of its units. This move represents a significant step in the Company's journey towards expanding its presence in the United States market.
Details of the Proposed Offering
The proposed offering will consist of units, each of which includes one common share of the Company and one share purchase warrant. These warrants will allow holders to purchase additional shares at a specified price, creating a compelling investment opportunity for future investors.
Innocan has also applied for its common shares and warrants to be listed on the Nasdaq Capital Market under the codes "INNP" and "INNPW", respectively. This is an important milestone as the company seeks to enhance its visibility in the U.S. stock markets, benefitting from the greater flexibility and potential provided by Nasdaq listing.
Role of ThinkEquity in the Offering
ThinkEquity has been designated as the sole book-running manager for this anticipated offering. Their expertise will help guide Innocan through this complex process, ensuring that the offering reaches its target audience effectively.
Potential investors will have access to a preliminary prospectus that outlines the mechanics of the offering, including terms and conditions. This document will be available when the SEC provides the necessary approvals.
Insights from Innocan's CEO
Iris Bincovich, CEO of Innocan Pharma, expressed excitement about the company taking this significant step towards listing on Nasdaq, highlighting that this venture opens up enticing new opportunities for the company on various levels. Bincovich emphasized the positive implications this has for Innocan's growth and the delivery of value to its stakeholders.
About Innocan Pharma
Innocan is a trailblazer in the pharmaceuticals and wellness sectors. It has developed a unique CBD-loaded liposome drug delivery platform, which allows for precise dosing and a controlled release of CBD for pain management. The company's mission extends into the wellness sector, where it offers a diverse range of self-care and beauty products aimed at enhancing a healthier lifestyle.
Its subsidiary, BI Sky Global Ltd., primarily drives the advanced online sales strategy, ensuring that Innocan's products reach a broad audience effectively. Innocan is committed to innovation in both the pharmaceutical and wellness industries, continually exploring ways to improve and expand its product offerings.
Company Contact Information
For further information regarding Innocan Pharma, interested parties can contact Iris Bincovich, the CEO. She is available through various channels, including phone numbers for international inquiries.
Frequently Asked Questions
What is the proposed public offering by Innocan Pharma?
The offering comprises units that include common shares and warrants, aimed at increasing its market presence.
When will the preliminary prospectus be available?
The preliminary prospectus will be released once the SEC approves the registration statement.
What exchange will Innocan Pharma be listed on?
Innocan Pharma intends to list its shares on the Nasdaq Capital Market under the symbols INNP and INNPW.
Who is managing the offering?
ThinkEquity is the sole book-running manager for Innocan's proposed public offering.
What are Innocan's main business areas?
Innocan operates in pharmaceuticals, focusing on innovative drug delivery systems, and wellness, providing self-care and beauty products.
